| treatment |
|
comparator |
death (overall survival) | progression or death (progression free survival PFS) |
|
|
| Eribulin | advanced breast cancer (metastatic), in all type of patients | vs capecitabine | NS | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.88 [0.77 1.00] | p=1.00 | 0 | 1102 | 1 | Trial 301 (Kaufman), | | progression or death (progression free survival PFS) | 1.08 [0.93 1.25] | p=1.00 | 0 | 1102 | 1 | Trial 301 (Kaufman), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Trial 301 (Kaufman), 2015 | eribulin
mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 [expressed as free
base]) intravenously over 2 to 5 minutes on days 1 and 8
until disease progression, unacceptable toxicity, or
patient/investigator request to discontinue | capecitabine
1.25 g/m2 orally twice per day on days 1 to 14, both in 21-day cycles | patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane |
|
| Eribulin | advanced breast cancer (metastatic), in all type of patients | vs ixabepilone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Vahdat, 2013 | eribulin mesylate (1.4 mg/m2, 2–5 min
intravenous on days 1 and 8) | ixabepilone (40 mg/m2,
3 h intravenous on day 1) on a 21-day cycle | patients with metastatic breast cancer |
|
| Eribulin | advanced breast cancer (metastatic), in all type of patients | vs treatment of physician | by 19% [demonstrated] | NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.81 [0.66 0.99] | p=0.04 | 0 | 762 | 1 | EMBRACE (Cortes), | | progression or death (progression free survival PFS) | 0.87 [0.72 1.06] | p=1.00 | 0 | 762 | 1 | EMBRACE (Cortes), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EMBRACE (Cortes), 2011 | eribulin mesilate (1·4 mg/m² administered intravenously during 2–5 min on days 1 and 8 of a 21-day
cycle) | treatment of physician’s choice | patients with metastatic breast cancer who had received between two and fi ve previous chemotherapy
regimens (two or more for advanced disease), including an anthracycline and a taxane, unless contraindicated. |
|
